MedTrace Logo

Phase I Trial of Periocular Topotecan in Retinoblastoma

NCT00460876 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2008-05-02

No results posted yet for this study

Summary

This is a dose-escalation study aimed to assess the toxicity (and marginally the activity) of periocular topotecan in patients with relapsed-resistant retinoblastoma.

Conditions

  • Retinoblastoma

Interventions

DRUG

Topotecan

Sponsors & Collaborators

  • Hospital JP Garrahan

    lead OTHER_GOV

Principal Investigators

  • Guillermo L Chantada, MD · Hospital JP Garrahan

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2007-12-31
Completion
2008-04-30

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00460876 on ClinicalTrials.gov